Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery
| Autor: | Ahizechukwu C. Eke, Elizabeth Oler, Ashley Hesson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Isi web of science
medicine.medical_specialty MEDLINE Injections Intramuscular law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Pregnancy Recurrence 17 alpha-Hydroxyprogesterone Caproate medicine Hydroxyprogesterones Humans 030212 general & internal medicine Preterm delivery Progesterone Randomized Controlled Trials as Topic Gynecology 030219 obstetrics & reproductive medicine business.industry Obstetrics Obstetrics and Gynecology 17α-Hydroxyprogesterone General Medicine medicine.disease Confidence interval Administration Intravaginal Meta-analysis Relative risk Premature Birth Female Progestins business medicine.drug |
| Zdroj: | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 138(1) |
| ISSN: | 1879-3479 |
| Popis: | Background Vaginal progesterone and 17α-hydroxyprogesterone (17α-OHP) are both used to prevent preterm delivery in women who have experienced spontaneous preterm delivery (SPTD) previously. Randomized trial data of the comparative effectiveness of these interventions have been mixed. Objectives To compare the efficacy of intramuscular 17α-OHP and vaginal progesterone in the prevention of recurrent SPTD. Search strategy Cochrane Central Register of Controlled Trials, African Journals Online, Embase, Google Scholar, ISI Web of Science, LILACS, CINAHL, PubMed, and registers of ongoing trials were searched using keywords related to 17α-OHP, vaginal progesterone, and preterm delivery. Selection criteria Randomized controlled trials published between January 1, 1966, and November 30, 2016, comparing 17α-OHP and vaginal progesterone for the prevention of recurrent SPTD during singleton pregnancies were included. Data collection and analysis Study data were extracted and meta-analyses were performed when outcomes were comparable. Main results The meta-analyses included data from three randomized trials. Lower rates of SPTD before 34 weeks (relative risk 0.71, 95% confidence interval 0.53–0.95) and before 32 weeks (relative risk 0.62, 95% confidence interval 0.40–0.94) of pregnancy were observed among patients treated with vaginal progesterone. Conclusions Vaginal progesterone and 17α-OHP were comparable for the prevention of recurrent SPTD in singleton pregnancies; vaginal progesterone could be superior. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text